NRX Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Mar 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 23, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 14. Principal Accounting Fees and Services
Item 14. Principal Accountant Fees and Services
Weinberg & Company, P.A. (“Weinberg”) served as our independent auditor for the year ended December 31, 2025. Salberg & Company, P.A (“Salberg”) served as our independent auditor for the years ended December 31, 2024 and December 31, 2023. The Company also incurred certain fees during the years ended December 31, 2024 and December 31, 2023 for audit services rendered by KPMG LLP. The Company incurred the following fees from Salberg and KPMG LLP for the audit of the consolidated financial statements and for other services provided during the years ended December 31, 2024 and from Weinberg and Salberg during the years ended December 31, 2025:
| 2025 · 2024 | |||
|---|---|---|---|
| Audit fees, KPMG LLP(1) | $ | - | $218,000 |
| Audit fees, Salberg and Company(1) | 98,000 | 250,000 | |
| Audit fees, Weinberg & Company, P.A. (1) | 150,000 | — | |
| Audit-related fees, Salberg and Company (2) | — | — | |
| Audit-related fees, Weinberg & Company, P.A. (2) | 76,000 | — | |
| Tax fees(3) | — | — | |
| All other fees(4) | — | — | |
| Total fees | $324,000 | $468,000 | |
| (1) | Audit fees consist of fees for professional services rendered in connection with the audit of our annual consolidated financial statements, the review of the consolidated financial statements included in quarterly reports, services rendered in connection with the May 2021 merger and follow-on public offering, and additional public offerings. |
| (2) | Audit-related fees billed in 2025 consist of fees for professional services rendered by Weinberg in connection with the audit of Dura Medical, LLC that was covered by the Company. The were no audit-related fees billed in 2024. |
| (3) | There were no tax-related fees billed in 2025 and 2024. |
| (4) | There were no other fees billed in 2025 and 2024. |
Audit Committee Pre-Approval Policy and Procedures
Consistent with requirements of the SEC and the Public Company Accounting Oversight Board regarding auditor independence, our Audit Committee is responsible for the appointment, compensation, and oversight of the work of our independent registered public accounting firm. In recognition of this responsibility, our Audit Committee (or the chair if such approval is needed on a time urgent basis) pre-approves audit and permissible non-audit services provided by the independent registered public accounting firm. These services include audit services, audit-related services, tax services and other services.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.